Galimedix Therapeutics, Inc. Email Format

Pharmaceutical ManufacturingMaryland, United States11-50 Employees

Galimedix Therapeutics, Inc. is a Phase 2 biotechnology company focused on neuroprotection and disease modification. Based in Kensington, Maryland, the company develops therapies aimed at slowing or stopping the progression of neurodegenerative diseases and preserving function in glaucoma and dry age-related macular degeneration, two major causes of blindness, as well as in Alzheimer's disease. The organization operates within the pharmaceutical development sector, pursuing candidates to address these brain and eye conditions. It maintains a relatively small to mid-sized team. In March 2026, Galimedix disclosed preclinical data for a next-generation oral Alzheimer's candidate, signaling pharmacokinetic improvements that could support lower dosing and longer-term use. This development highlights the company's ongoing efforts to advance therapies across both neurodegenerative and ophthalmic indications.

Get verified Galimedix Therapeutics, Inc. emails free

Company overview Employee directory